




The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 0.098% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is 0.15%, being 214% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	2,352
Cost of Goods Sold	96
Intangible Assets	2,044
Liabilities, Current	2,938
Liabilities, Non-Current	588
Other Assets	788
Other Compr. Net Income	0
Other Expenses	-1,546
Other Liabilities	42
Other Net Income	-28,835
Other Revenues	582
Property and Equipment	85
Research and Development	4,604
Selling, General and Administrative Expense	13,132

Output Variable	Value in 1000 USD
Assets	5,269
Liabilities	3,568
Expenses	16,286
Revenues	582
Stockholders Equity	1,701
Net Income	-44,539
Comprehensive Net Income	-44,539
BaseVar	27,270
ECR before LimitedLiability	-924%
Economic Capital Ratio	0.15%